Regnante Keith
CHIEF FINANCIAL OFFICER
Regnante Keith has filed 1 SEC Form 4 filing (1 transaction rows) across 1 company, with disclosures dating back to 2026. 1 of those filings fall inside the rolling window. Most recent filing: Feb 20, 2026.
On the most recent filing, Regnante Keith is listed as CHIEF FINANCIAL OFFICER at Keros Therapeutics, Inc. Inside the rolling window, Regnante Keith reported no open-market purchases and 1 open-market sale totaling $77K in KROS.
Companies traded
Other insiders at KROS
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$77K
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Regnante Keith made?
Regnante Keith has filed 1 SEC Form 4 filing (1 transaction rows) across 1 company since 2026.
Which companies does Regnante Keith trade?
Regnante Keith has filed SEC Form 4 disclosures for 1 company, including KROS.
When was Regnante Keith's most recent SEC Form 4 filing?
Regnante Keith's most recent SEC Form 4 filing on Tracefour is dated Feb 20, 2026.
What is Regnante Keith's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Regnante Keith is listed as CHIEF FINANCIAL OFFICER.
What is Regnante Keith's total buy and sell value in the current window?
Inside the rolling retention window, Regnante Keith bought $0 and sold $77K based on SEC Form 4 filings.
What was Regnante Keith's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 4,739 KROS shares on 2026-02-18, worth $77K, per SEC Form 4 filings.